No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

in StudyGraphics

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025

Long-term dual antiplatelet therapy does not increase mortality risk

Hematology

Sanofi wins approval for first Bruton’s tyrosine kinase inhibitor in immune thrombocytopenia

September 9, 2025

Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]

September 3, 2025

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports